Faget Quoted in MedTech Dive on the FDA’s Response to the COVID Crisis
March 15, 2021
MedTech Dive
Kyle Faget, partner and member of the firm’s Health Care and Life Sciences Industry Team, was quoted in a MedTech Dive article titled, “5 Things Medtech Can Expect from FDA in 2021.”
Faget told MedTech Dive that she sees the FDA in 2021 releasing its long-awaited publication of the revised Quality System Regulation. She also stated that: “What we saw a lot of in the Trump administration was HHS getting very involved in FDA’s business and we’re going to see less of that.” She continued, “There’s going to be much more deference to FDA as an independent regulatory body.”
Related News
October 23, 2026
In the News
Marisa White and Rena Andoh Garnered Broad Media Coverage Following Foley Arrival
Foley & Lardner LLP partners Marisa White and Rena Andoh are featured across the media following their recent arrival to the firm's New York Office.
October 22, 2026
In the News
Louis Lehot Authors Article on Year-End Planning for Founders and Boards
Foley & Lardner LLP partner Louis Lehot authored the Insights: The Corporate & Securities Law Advisor article, “Five Moves Founders and Boards Should Make Before 2026 Ends,” offering guidance for companies navigating tax, governance, AI, capital raising, and M&A considerations as they prepare for 2027.
October 21, 2026
In the News
Sunita Paknikar Recognized as Rising Star Corporate Winner at Law.com's D.C. Legal Awards
Foley & Lardner LLP senior counsel Sunita Paknikar is featured in Law.com as the Rising Star Corporate winner at the 2026 DC Legal Awards.